Amgen Pays $240m for Michigan Spinoff’s Dendritic Cell Targeting Molecules for Autoimmune Disorders
January 14, 2021
The multinational biopharmaceutical company Amgen has announced it will pay $240 million in upfront cash and milestone payments for molecules targeting autoimmune conditions from Ann Arbor, MI-based Evoq Therapeutics, a spinoff of research from the University of Michigan. Evoq, founded by Profs. Anna Schwendeman and James Moon, is named for the targeted dendritic cells the company uses to “evoke” immune tolerance in regulatory T cells.
Read more about the pair’s research and their new partnership with Amgen.
Latest News
Professor Amanda Garner Named Charles Walgreen, Jr. Professor
March 28, 2025
Author: Markie Heideman, Content Marketing Manager Media Contact: Lindsay Groth, Director of Marketing and Communications, [email protected] Amanda Garner, PhD, has been named Charles Walgreen, Jr. Professor of Medicinal Chemistry, as approved by the Regents of the University of Michigan. Both The Charles Walgreen, Jr. Professorship created in December 2024 and the already-established Charles R. Walgreen, […]
Professor Shiyanbola Elected to Behavioral Medicine Fellowship
March 27, 2025
This SBM fellowship is not only a recognition of Dr. Shiyanbola’s hard work but an opportunity to mentor early-career investigators.
Dr. Hanna Phan Selected for Excellence Award in Pediatric Pharmacy Practice
March 21, 2025
Dr. Phan’s dedication to improving pediatric health outcomes, particularly in pulmonology, and her passion for mentorship and education have earned her this prestigious honor.